GeneLink BioSciences, Inc. ANNOUNCES THE FILING OF U.S. PATENT APPLICATION FOR SNPS BASED METHOD TO DETECT SUSCEPTIBILITY TO CONNECTIVE TISSUE BREAKDOWN AND SKIN AGING
October 30, 2001

MARGATE, NJ - (Business Wire) - October 30, 2001 - The World's First Family Centered DNA Bank and Hereditary Genetic Information Service, today announced that it has filed a patent application through the Philadelphia office of international law firm - Akin, Gump, Struass, Hauer & Feld. L.L.P., for a proprietary genetic test that predicts an individual's susceptibility to conditions that lead to accelerated skin aging and connective tissue breakdown.

In this newly filed patent, GeneLink's oxidative stress profile not only measures an individual's inherent ability to defend against oxidative stress, it also examines a variant of this gene in which oxidative stress can greatly increase susceptibility to connective tissue breakdown and premature skin aging. Consumers can be easily tested for the genetic variation by utilizing GeneLink's patented oral home swab kit and mailing it to GeneLink's labs for evaluation. Based on GeneLink's proprietary genetic test, specifically formulated skin care products that block oxidative stress can be used to reduce expression of this variant gene and retard skin aging.

GeneLink is collaborating with a major skin care formulator and raw ingredient supplier to produce products that alleviate oxidative stress and other age related deficiencies in the skin. On September 24th, Arch Chemicals' (NYSE: ARJ) Personal Care Unit and GeneLink announced that they entered into a strategic partnership to develop such products based on a consumer's genetic makeup. Arch Personal Care Products, L.P., a business unit with Arch's Treatment Products business segment, sells a variety of unique products to businesses in the cosmetics and toiletries arena, an approximately $40 billion US retail market (May 14, 2001 Chemical Market Reporter).

"The use of genetic information from GeneLink's profiles will have a tremendous application in the skincare industry," say's John R DePhillipo, Chairman and CEO of GeneLink, "This adds to GeneLink's expanding arsenal of proprietary genetic profile tests and will result in the development of some remarkable new products to help people combat skin aging. We anticipate new products could be ready for worldwide distribution in the early part of 2002," adds DePhillipo.

Forward-Looking Statements: This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a new "safe harbor" for these types of statements.

SOURCE: GeneLink BioSciences, Inc.